Trusted Resource for Clinical Trials, Protocols & Progress
Protocol deviations (PDs) are critical indicators of a clinical trial site’s operational discipline, training adequacy, and regulatory compliance. Reviewing historical deviation patterns across a site’s prior trials enables sponsors and CROs to predict future risks, evaluate data integrity, and identify sites needing additional oversight or requalification.
Click to read the full article.
Clinical trial sponsors and CROs often engage sites repeatedly across multiple protocols and therapeutic areas. Yet, not all site performances are equal—some consistently exceed expectations while others underperform. Benchmarking site performance across studies enables feasibility teams to identify high-value partners, optimize site portfolios, and reduce trial risk through objective data-driven selection.
Click to read the full article.
While much attention is given to high-performing clinical trial sites, underperforming sites hold equally valuable insights. Whether it’s delays in startup, failure to enroll, data quality issues, or protocol non-compliance, these sites represent high-risk nodes that impact trial timelines, regulatory confidence, and overall study cost. Reviewing lessons from past site underperformance is critical for enhancing feasibility planning, refining site selection SOPs, and building future-ready oversight systems.
Click to read the full article.
In an era of data-driven decision-making, investigator site selection can no longer rely solely on subjective reputation or ad hoc feasibility questionnaires. Sponsors and CROs now leverage performance scorecards—quantitative tools that aggregate site metrics across past trials—to ensure high-quality, compliant, and efficient clinical trial execution.
Click to read the full article.
When a clinical trial site fails to meet operational expectations—such as subject enrollment, protocol adherence, or data quality—it often foreshadows deeper issues in Good Clinical Practice (GCP) compliance. Regulators like the FDA, EMA, MHRA, and others use both performance indicators and inspection findings to assess whether a site or sponsor is consistently meeting obligations under ICH E6(R2).
Click to read the full article.
In today’s clinical research environment, subjective feasibility questionnaires and anecdotal feedback are no longer sufficient to evaluate investigator site performance. Sponsors and CROs increasingly rely on structured, real-time data sources—most notably, Electronic Data Capture (EDC) systems and Clinical Trial Management Systems (CTMS)—to assess a site’s operational efficiency, compliance history, and future suitability for study participation.
Click to read the full article.
Site selection in clinical trials has traditionally relied on feasibility questionnaires, investigator self-reporting, and sponsor relationships. However, this approach often overlooks objective indicators of operational risk—leading to poor enrollment, data quality concerns, and regulatory issues. Risk scoring based on historical site metrics enables sponsors and CROs to assign quantitative risk levels to each site, guiding feasibility, oversight intensity, and regulatory preparedness.
Click to read the full article.
